Wealth Enhancement Advisory Services
PACB icon

Wealth Enhancement Advisory Services’s Pacific Biosciences PACB Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,000
Closed -$7K – 2891
2024
Q2 		$7K Buy
+50,000
New +$101K ﹤0.01% 2531

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wealth Enhancement Advisory Services's PACB Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Pacific Biosciences (PACB) stake by 26% in Q2 2026, buying an estimated $16.5K and bringing the position to 54,981 shares worth $85.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3833.

Wealth Enhancement Advisory Services first reported a position in PACB in Q3 2023 and has held it in 12 quarters since. The position peaked at $162K in Q4 2023. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Wealth Enhancement Advisory Services held 54,981 shares of Pacific Biosciences worth $85.8K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 11,320 Pacific Biosciences shares in Q2 2026, an estimated $16.5K.
  • Pacific Biosciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3833 holding.
  • Wealth Enhancement Advisory Services first reported a position in Pacific Biosciences in Q3 2023 and has held it in 12 quarters since.
  • Wealth Enhancement Advisory Services's Pacific Biosciences position peaked at $162K in Q4 2023.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.